RECURSIVE PARTITIONING ANALYSIS FOR GENETIC STRATIFICATION AND PROGNOSTICATION OF ACUTE MYELOID LEUKAEMIA

EHA Library, Shaun Fleming, 133458

CD7 AND CD34 CO-EXPRESSION IDENTIFY A SUBPOPULATION OF NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA (NPM1+ AML) PATIENTS WITH INCREASED RISK OF RELAPSE.

EHA Library, Anna Porwit, 133459

IMPACT OF FIRST LINE ARSENIC TRIOXIDE AND RETINOIC ACID TREATMENT ON OUTCOME IN THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS

EHA Library, Sabine Kayser, 133460

AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH MYELODYSPLASIA-RELATED CHANGES (MRC) IN AZA-AML-001 PER CENTRAL REVIEW

EHA Library, John F Seymour, 133461

IMPACT OF PHYSICIANS’ CHARACTERISTICS ON DECISION MAKING IN ELDERLY ACUTE MYELOID LEUKEMIA

EHA Library, Pierre Bories, 133462

THE ADDITION OF GEMTUZUMAB OZAGAMICIN (GO) TO INTENSIVE CHEMOTHERAPY SIGNIFICANTLY IMPROVES COMPLETE RESPONSES CR RATES AND OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

EHA Library, Chiara Sartor, 133463

HOSPITALIZATION FOR TREATMENT-EMERGENT ADVERSE EVENTS (TEAE) IN OLDER (≥65 YEARS) PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WITH >30% MARROW BLASTS IN THE PHASE 3 AZA-AML-001 STUDY

EHA Library, John F Seymour, 133464

PHARMACEUTICAL TARGETING OF PYRUVATE DEHYDROGENASE KINASES IN T(8;21) ACUTE MYELOID LEUKEMIA

EHA Library, Hüsün Kizilkaya, 133465

HOPX IS A HEMATOPOIETIC STEM CELL MARKER AND ITS HIGH EXPRESSION PREDICTS CHEMORESISTANCE IN DE NOVO ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Chien-Chin Lin, 133466

KIT MUTATIONS INCREASE THE RELAPSE RISK IN PATIENTS WITH AML WITH T(8;21) OR RUNX1-RUNX1T1 BUT NOT IN PATIENTS WITH INV(16) OR CBFB/MYH11: A SUBGROUP ANALYSIS OF CETLAM PROTOCOLS 2003 & 2012

EHA Library, Marta PRATCORONA, 133467

LONGITUDINAL EVALUATION OF T-CELLS IN CLINICAL MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL)

EHA Library, Sameer Parikh, 133468

COPY NUMBER ANALYSIS OF THE BIRC3 GENE BY DROPLET DIGITAL PCR IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 11Q DELETION

EHA Library, Sara Raponi, 133469

CLONAL EVOLUTION IN CLL IS ASSOCIATED WITH AN UNMUTATED IGHV STATUS, MUTATED TP53 AND SHORTER SURVIVAL

EHA Library, Claudia Haferlach, 133470

EPIGENETIC REGULATION OF ROR1 IN CHRONIC LYMPHOCYTIC LEUKEMIA DEFINES PREFERABLE TARGET FOR COMBINED EPIGENETIC-AND IMMUNE-THERAPY

EHA Library, Katarzyna Skorka, 133472

COMPLEX KARYOTYPE AS IDENTIFIED BY CHROMOSOME BANDING ANALYSIS IS ASSOCIATED WITH SHORTER OVERALL SURVIVAL IN CLL INDEPENDENT OF TP53 ALTERATION AND IGHV MUTATION STATUS

EHA Library, Claudia Haferlach, 133473

IMPROVING THE DIFFERENTIAL DIAGNOSIS OF CD5+ B-LYMPHOPROLIFERATIVE DISORDERS

EHA Library, Andy Rawstron, 133474

REFINED KARYOTYPE-BASED PROGNOSTIC STRATIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH A VERY LOW RISK GENETIC PROFILE

EHA Library, Ilaria Del Giudice, 133475

PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS

EHA Library, Zuzana Jaskova, 133476

PILOT STUDY TO ASSESS REAGENT AND INSTRUMENT QUALITY FOR REPRODUCIBLE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: AN ESCCA AND ERIC HARMONISATION PROJECT

EHA Library, Andy Rawstron, 133477

THE SYK\JAK INHIBITOR CERDULATINIB SHOWS PROMISING IN VITRO ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Andrew J. Steele, 133478

SAFETY, EFFICACY AND IMMUNE EFFECTS OF VENETOCLAX 400 MG DAILY IN PATIENTS (PTS) WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Mary Ann Anderson, 133479

IBRUTINIB FOR RELAPSED CLL PATIENTS OLDER THAN 75 YEARS: PROVEN EFFICACY, TOXICITIES TO KNOW

EHA Library, Anne-Sophie Michallet, 133480

MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY

EHA Library, Sven Estenfelder, 133481

IDELALISIB IN COMBINATION WITH RITUXIMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL): REAL-WORLD EXPERIENCE THROUGH AN EARLY ACCESS PROGRAM IN EUROPE AND AUSTRALIA

EHA Library, Julio Delgado, 133482

CHROMOSOME 8 ABNORMALITIES ARE ASSOCIATED WITH AN EVEN WORSE OUTCOME AND KARYOTYPE COMPLEXITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND TP53 ABERRATIONS

EHA Library, Anna Puiggros, 133483

OUTCOMES WITH SINGLE-AGENT IBRUTINIB BY PRIOR LINE OF THERAPY AND FOLLOWING IBRUTINIB DISCONTINUATION IN PATIENTS WITH CLL: ANALYSES FROM PHASE 3 STUDIES

EHA Library, Peter Hillmen, 133484

SINGLE-AGENT IBRUTINIB VS STANDARD OF CARE FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ADJUSTED COMPARISON OF RESONATE™ WITH THE CLLEAR DATABASE

EHA Library, Michael Doubek, 133485

NO IMPROVEMENT IN LONG-TERM OVERALL SURVIVAL AFTER THE INTRODUCTION OF CHEMO(IMMUNO)THERAPY FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS BELONGING TO STEREOTYPED SUBSET #2

EHA Library, Panagiotis Baliakas, 133486

VENETOCLAX IS ACTIVE IN CLL PATIENTS WHO HAVE RELAPSED AFTER OR ARE REFRACTORY TO IBRUTINIB OR IDELALISIB

EHA Library, Steven E Coutre, 133487

SOMATIC MUTATIONS IN NEWLY-DIAGNOSED CHRONIC MYELOID LEUKEMIA DETECTED BY WHOLE-EXOME SEQUENCING

EHA Library, Chiaki Nakaseko, 133488

ROCK AS THERAPEUTICAL TARGET FOR MORGANA LOW CML

EHA Library, Stefania Rocca, 133489

A NOVEL C-TERMINAL HSP90 INHIBITOR WITH THERAPEUTIC EFFECT IN IMATINIB RESISTANT CML.

EHA Library, Sanil BHATIA, 133490

RESISTANCE IN CHRONIC MYELOID LEUKEMIA: THERAPEUTIC TARGETING OF ESCAPE VIA CSF2RB

EHA Library, Constance Becker, 133491

MITOCHONDRIAL DNA MUTATIONS IDENTIFY CLONAL HETEROGENEITY IN CHRONIC MYELOID LEUKAEMIA

EHA Library, Ilaria Pagani, 133492

CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA

EHA Library, Paresh Vyas, 133493

ROLE OF THE AURORA KINASE A AXIS IN IMATINIB RESISTANCE OF CHRONIC MYELOID LEUKEMIA CD34+ PROGENITORS

EHA Library, Manuela Mancini, 133494

PRESENCE OF SOMATIC AND GERMLINE MUTATIONS IN EPIGENETIC MODIFIERS IN CML-CP

EHA Library, Georgios Nteliopoulos, 133495

ASSESSMENT OF BCR-ABL1 TRANSCRIPT LEVELS BY DIGITAL PCR (DPCR) IN 116 PH+ CML PATIENTS TREATED WITH TIROSIN KINASE INHIBITORS (TKIS): A COMPARATIVE ANALYSIS BETWEEN DPCR AND QPCR.

EHA Library, Simona Bernardi, 133496

MOLECULAR RESPONSES OF B2A2 BCR-ABL1 TRANSCRIPT ARE INFERIOR TO B3A2 TYPE IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT CHRONIC PHASE TREATED WITH FRONTLINE IMATINIB -TAIWAN CML STUDY

EHA Library, Ming-Chung Wang, 133497

THE INCIDENCE AND NATURAL HISTORY OF DASATINIB COMPLICATIONS IN THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA

EHA Library, Lucy Fox, 133498

THE HOCT1/ABCB1 DIPLOTYPE IS ASSOCIATED WITH COMPLETE CYTOGENETIC RESPONSE AND TOLERABILITY TO IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA

EHA Library, Sara Galimberti, 133499

REAL-LIFE COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER IMATINIB FAILURE FOR CHRONIC PHASE CML

EHA Library, Mario Tiribelli, 133500

FACTORS THAT INFLUENCE PATIENT WILLINGNESS TO ATTEMPT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKAEMIA

EHA Library, David Ross, 133501

GENETIC VARIABILITY OF OXIDATIVE STRESS AND DNA REPAIR GENES – POTENTIAL PROGNOSTIC AND THERAPEUTIC BIOMARKERS IN CHRONIC MYELOID LEUKEMIA

EHA Library, Ana Cristina Gonçalves, 133502

LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS

EHA Library, Michele Baccarani, 133503

BCR-ABL1 TRANSCRIPT LEVEL ON DAY+28 CAN PREDICT EARLY MOLECULAR RESPONSE AT 3 MONTHS AND MAJOR MOLECULAR RESPONSE AT 12 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS WHO TREATED WITH FRONTLINE DASATINIB

EHA Library, Won Sik Lee, 133504

THE IMPACT OF EARLY MOLECULAR RESPONSE ON LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH DASATINIB OR IMATINIB FROM THE DASISION TRIAL

EHA Library, Frank Stegelmann, 133505

IMPACT OF AZACITIDINE THERAPY ON OVERALL SURVIVAL OF NEWLY DIAGNOSED PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES: A POST HOC ANALYSIS OF THE ERASME STUDY

EHA Library, Regina García, 133506

IMPACT OF BONE MARROW FIBROSIS IN RESPONSE TO AZACITIDINE IN 94 PATIENTS WITH MYELODISPLASTIC SYNDROMES (MDS), CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND ACUTE MYELOID LEUKEMIA

EHA Library, Gianluigi Reda, 133507

AGE DISTRIBUTION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) IN GERMANY AND THEIR PROGNOSIS ACCORDING TO THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS): DATA FROM THE REGULAR CARE MDS REGISTRY

EHA Library, H Tilman Steinmetz, 133508

VALIDATION OF PROGNOSTIC SCORING SYSTEMS FOR MYELODYSPLASTIC SYNDROMES IN THE SWEDISH MDS-REGISTER

EHA Library, Daniel Moreno Berggren, 133509

EXPRESSION OF TUBB GENE IN MYELODYSPLASTIC SYNDROME WITH OR WITHOUT EVOLUTION TO LEUKEMIA

EHA Library, Yan Ma, 133510

HIDDEN MDS: A PROSPECTIVE STUDY TO CONFIRM OR EXCLUDE MDS IN PATIENTS WITH ANEMIA OF UNCERTAIN ETIOLOGY.

EHA Library, Jose Maria Bastida Bermejo, 133511

MANAGEMENT OF IRON OVERLOAD WITH DEFERASIROX IN VARIOUS HEMATOLOGICAL MALIGNANCIES – REAL WORLD EXPERIENCES FROM THE GERMAN NON-INTERVENTIONAL STUDY EXSEPT

EHA Library, Forian Nolte, 133512

CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES (MDS) IN DAILY PRACTICE: A POPULATION-BASED STUDY AMONG 8912 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 2001 TO 2014

EHA Library, Avinash Dinmohamed, 133513

LEVELS OF TRANSFUSION BURDEN AND ASSOCIATED COSTS FOR PATIENTS WITH TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES

EHA Library, Amy Dezern, 133514

THE INCORPORATION OF COMORBIDITIES IN THE PROGNOSTICATION OF PATIENTS WITH LOWER-RISK MDS.

EHA Library, Teresa Knight Asorey, 133515

STROMAL MICROENVIRONMENT COMPONENTS DAMAGE IN PATIENTS WITH GRAFT FAILURE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION

EHA Library, Nataliya Petinati, 133516

SPONTANEOUS REMISSION IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA - RETURN TO HEALTH OR TRANSITION INTO MALIGNANCY?

EHA Library, Eva-Stina Kairemo, 133517

UNAFFECTED MYELOID DIFFERENTIATION OF IPS CELLS DERIVED FORM A CYCLIC NEUTROPENIA (CYN) PATIENT WITH ELANE MUTATION

EHA Library, Azadeh Zahabi, 133518

OUTCOME OF ADOLESCENT AND YOUNG ADULTS WITH ACQUIRED APLASTIC ANEMIA TREATED WITH IMMUNOSUPPRESSIVE THERAPY IN COMPARISON WITH CHILDREN AND OLDER ADULTS

EHA Library, Aurélie Cabannes-Hamy, 133519

A PHASE 1 SINGLE-ASCENDING-DOSE CLINICAL STUDY OF RA101495, A SUBCUTANEOUSLY ADMINISTERED SYNTHETIC MACROCYCLIC PEPTIDE INHIBITOR OF COMPLEMENT C5 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Jeffrey Johnston, 133520

THE PRESENCE OF A PNH CLONE INFLUENCES THE KINETICS OF RESPONSE TO IMMUNOSUPPRESSIVE THERAPY (IST) IN APLASTIC ANEMIA (AA) PATIENTS.

EHA Library, Emilie Nevill, 133521

A CLINICAL SIGNIFICANCE AND TIME-DEPENDENT CHANGE OF PNH CLONE SIZE IN PATIENTS WITH BONE BARROW FAILURE SYNDROME: JAPANESE MULTI-CENTRE PROSPECTIVE STUDY

EHA Library, Yukari Shirasugi, 133522

HLA-HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION ：A VALID ALTERNATIVE OPTION FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Feng Chen, 133523

GENE MUTATIONS IN INHERITED BONE MARROW FAILURE SYNDROME REVEALED BY NEXT GENERATION SEQUENCING: COMPARISON WITH CHROMOSOME BREAKAGE TEST

EHA Library, Si Nae Park, 133524

PROSPECTIVE STUDY ON THE USE OF PEGFILGRASTIM IN CHILDREN WITH SEVERE CONGENITAL NEUTROPENIA

EHA Library, Francesca Fioredda, 133525

IKAROS PROTEIN EXPRESSION IN BONE MARROW B AND T CELLS RATHER THAN MYELOMA CELLS PREDICTS OUTCOME AFTER LENALIDOMIDE-DEXAMETHASONE THERAPY

EHA Library, Arnold Bolomsky, 133526

CXCL13 CHEMOKINE – A NOVEL TARGET IN MULTIPLE MYELOMA MICROENVIRONMENT

EHA Library, Katia Beider, 133527

MESENCHYMAL STEM CELLS (MSC) PROMOTES TUMOR MICROENVIRONMENT TRANSFORMATION DRIVING GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSC) ACTIVATION IN SMOLDERING AND MULTIPLE MYELOMA PATIENTS

EHA Library, Daniele Tibullo, 133528

TARGETING OF BMI-1 WITH PTC-209 AFFECTS MYELOMA CELL GROWTH & SURVIVAL AND IMPAIRS THE TUMOUR MICROENVIRONMENT

EHA Library, Arnold Bolomsky, 133529

LENALIDOMIDE MAINTENANCE COUNTERACTS PD-1 ELEVATION ON LYMPHOCYTES IN MYELOMA PATIENTS

EHA Library, Sophia Danhof, 133530

CIRCULATING SERUM MIRNA PROFILE IN AL AMYLOIDOSIS

EHA Library, Katerina Growkova, 133531

PRECLINICAL EVALUATION OF ABBV-838, A FIRST-IN-CLASS ANTI-CS1 ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF MULTIPLE MYELOMA

EHA Library, Kurt Gish, 133532

SOLUBLE BCMA BINDS ITS LIGAND BAFF AND PREVENTS NORMAL ANTIBODY PRODUCTION IN MULTIPLE MYELOMA PATIENTS

EHA Library, James Berenson, 133533

DIFFERENTIAL EFFECTS OF ELOTUZUMAB (ANTI-SLAMF7) AND ANTI-CD38 MONOCLONAL ANTIBODIES IN PRECLINICAL MODELS

EHA Library, Natalie Bezman, 133534

NRF2 ACTIVITY IN BONE MARROW MESENCHYMAL STROMAL CELL PROTECTS MULTIPLE MYELOMA FROM CARFILZOMIB AND BORTEZOMIB INDUCED CELL DEATH

EHA Library, Yu Sun, 133535

PHASE 1B STUDY OF AN ALTERNATIVE LIQUID FORMULATION OF ACY-1215 (RICOLINOSTAT) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA

EHA Library, Sumit Madan, 133536

DEVELOPMENT OF A PREDICTIVE MODEL TO IDENTIFY PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANT AT RISK FOR SEVERE INFECTIONS USING DATA FROM THE FIRST TRIAL

EHA Library, Charles Dumontet, 133537

OUTCOME OF MYELOMA PATIENTS WITH DELETION 17P – IMPACT OF BASELINE CHARACTERISTICS, TREATMENT AND ADDITIONAL CHROMOSOMAL CHANGES

EHA Library, Maximilian Merz, 133538

CIRCULATING TUMOR DNA IN MULTIPLE MYELOMA

EHA Library, Even Rustad, 133539

SINGLE-AGENT IBRUTINIB IN RITUXIMAB-REFRACTORY PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA (WM): UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL PHASE 3 SUBSTUDY (INNOVATETM)

EHA Library, Meletios Dimopoulos, 133540

POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE IN PROTEASOME INHIBITOR–EXPOSED AND LENALIDOMIDE-REFRACTORY MYELOMA: RESULTS OF A MULTICENTER, DOSE-ESCALATION, PHASE 1 TRIAL (MM-005)

EHA Library, PAUL RICHARDSON, 133541

PROSPECTIVE COMORBIDITY AND FUNCTIONAL GERIATRIC ASSESSMENT (CF-GA) IN MULTIPLE MYELOMA (MM) PATIENTS (PTS): RESULTS FROM A MULTICENTER GERMAN STUDY GROUP MM (DSMM) TRIAL

EHA Library, Sandra Dold, 133542

IMPACT OF CYTOGENETIC RISK ON PFS2 OF PATIENTS TREATED WITH DIFFERENT THERAPY SEQUENCES: RESULTS OF A POST-HOC ANALYSIS

EHA Library, Massimo Offidani, 133543

A FRAILTY SCALE PREDICTS OUTCOMES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CONTINUOUS LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN THE FIRST (MM-020) TRIAL

EHA Library, Thierry Facon, 133544

PROSPECTIVE EVALUATION OF GERIATRIC ASSESSMENT TOOLS IN REAL-WORLD, UNSELECTED, ELDERLY PATIENTS WITH SYMPTOMATIC MYELOMA

EHA Library, Efstathios Kastritis, 133545

IS THERE A PROGNOSTIC IMPACT OF THE CEREBLON EXPRESSION IN MULTIPLE MYELOMA?

EHA Library, Jelena Bila, 133546

CARFILZOMIB AND DEXAMETHASONE VS SUBCUTANEOUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SECONDARY ANALYSIS FROM THE PHASE 3 STUDY ENDEAVOR (NCT01568866)

EHA Library, Hartmut Goldschmidt, 133547

PATIENT-REPORTED QUALITY OF LIFE WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) VS PLACEBO-RD IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN THE GLOBAL, PLACEBO-CONTROLLED TOURMALINE-MM1 STUDY

EHA Library, Xavier Leleu, 133548

WEEKLY CARFILZOMIB WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 STUDY CHAMPION-1 (NCT01677858)

EHA Library, James Berenson, 133549

DO MULTIPLE MYELOMA R/R PATIENTS BENEFIT FROM EARLY TREATMENT AT BIOLOGICAL RELAPSE? PRELIMINARY RESULTS OF A SPANISH OBSERVATIONAL PROSPECTIVE REGISTRY

EHA Library, Carlos Fernandez Delarrea, 133550

EFFICACY AND SAFETY BY CYTOGENETIC RISK STATUS: PHASE 3 STUDY (ASPIRE) OF CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA

EHA Library, Hervé Avet-Loiseau, 133551

A SUBSTUDY OF THE PHASE 3 ENDEAVOR STUDY: SERIAL ECHOCARDIOGRAPHIC ASSESSMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA (RMM) RECEIVING CARFILZOMIB PLUS DEXAMETHASONE OR BORTEZOMIB PLUS DEXAMETHASONE

EHA Library, Roman Hájek, 133552

PROGNOSTIC FACTORS IN PATIENTS WITH MULTIPLE MYELOMA AND STANDARD-RISK CYTOGENETICS

EHA Library, Moritz Binder, 133553

CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE

EHA Library, Georgia Metzgeroth, 133554

THROMBOTIC RISK IN IDIOPATHIC ERYTHROCYTOSIS IS LOWER THAN IN POLYCYTHEMIA VERA BUT HIGHER THAN IN GENERAL POPULATION.

EHA Library, Maria Luigia Randi, 133555

AZACITIDINE IN THE TREATMENT OF PH- MYELOPROLIFERATIVE NEOPLASMS IN BLASTIC PHASE: THE EXPERIENCE OF GRUPPO LAZIALE FOR THE STUDY OF PH- SMPC

EHA Library, Ambra Di Veroli, 133556

COMPARISON OF GENOMIC DNA-BASED VS. MESSENGER RNA-BASED KIT D816V MUTATION ANALYSIS REVEALS LARGE DIFFERENCES BETWEEN BLOOD AND BONE MARROW IN SYSTEMIC MASTOCYTOSIS

EHA Library, Thomas Kristensen, 133557

3167 NEWLY DIAGNOSED MPN PATIENTS, A REPORT FROM THE SWEDISH MPN REGISTRY

EHA Library, Björn Andréasson, 133558